Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma

Completed · Not applicable

Conditions studied: Multiple Myeloma

In brief

Primary Objectives: 1. To evaluate clinical tolerance and response to curcumin alone and in combination with Bioperine in patients with multiple myeloma. 2. To compare the pharmacokinetics and pharmacodynamics of curcumin and curcumin + Bioperine and evaluate the effect of Bioperine on the bioavailability of curcumin. 3. To evaluate the biologic effects of curcumin alone and in combination with Bioperine on the expression of NF-kB and related genes in the Multiple Myeloma (MM) cells.

Key facts

Study ID

NCT00113841

Run by

M.D. Anderson Cancer Center

People needed

42

Starts

2004-11-01

Expected to finish

2009-08-01

Last updated by the study team

2011-11-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with multiple myeloma who have been previously untreated, are asymptomatic and without serious or imminent complications; or have relapsed or failed treatment with conventional therapy.
• Adequate hematologic, renal, and hepatic functions.
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

You may not qualify if…

• Previously untreated patients with high tumor mass; symptomatic or impending fractures.
• Patients with significant cardiac disease.
• Patients with comorbid condition which renders patients at high risk of treatment complications.
• History of significant neurological or psychiatric disorders.

Where it is running

• U.T.M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.